Introduction: Elevated oxidized low-density lipoprotein (oxLDL) was shown to be related to atherosclerotic cardiovascular diseases, but the role of oxLDL in predicting recurrent stroke in patients with minor stroke or transient ischemic attack remains unclear. We aimed to investigate the association between oxLDL and recurrent stroke.
Methods: In the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial, baseline oxLDL levels were measured. The primary outcomes were any stroke within 90 days and 1 year. The association of oxLDL with recurrent stroke was analyzed by using Cox proportional hazards model.
Results: Among the 3019 patients included in this study, the median (IQR) of oxLDL was 13.96 (6.65-28.81) ug/dl. After adjusted for conventional confounding factors, patients in the highest oxLDL quartile had a higher risk of recurrent stroke within 90 days (HR, 1.42; 95% CI, 1.02-1.96) and 1 year (HR, 1.41; 95% CI, 1.05-1.90) compared with the lowest oxLDL quartile. There was no significant interaction between oxLDL levels and randomized antiplatelet therapy.
Conclusions: Elevated oxLDL levels can independently predict recurrent stroke in patients with minor stroke or transient ischemic attack.